Mirati Therapeutics Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Mirati Therapeutics Inc 's ROA in the third quarter of 2023?
Mirati Therapeutics Inc recorded a cumulative net loss of $-726 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -70.03%.

However, within the Healthcare sector 792 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 4685, from total ROA ranking in the second quarter of 2023 at 4782.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter
Y / Y Total Assets Change	-13.76 %	-29.08 %	-27.8 %	-26.43 %	4.33 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-726	-738	-737	-741	-738
Return On Assets (TTM)	-70.03 %	-68.28 %	-62.96 %	-58.48 %	-53.8 %
MRTX's Total Ranking	# 4685	# 4782	# 4865	# 5568	# 4912
Total Assets (TTM) in million	1,095	883	1,000	1,169	1,270
Seq. Total Assets Change	24.02 %	-11.69 %	-14.49 %	-7.93 %	2 %
Seq. Net Income Change	-	-	-	-	-

MRTX's 5 Years Annual ROA >> Back to MRTX Management Effectiveness >> Compare MRTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 365
Sector	# 793
Overall	# 4598

Return On Assets Statistics
High	Average	Low
29.81 %	-56.39 %	-96.7 %
(Sep 30 2014)		(Dec 31 2014)

Financial Statements
Mirati Therapeutics Inc 's Assets	$ 1,095 million	MRTX's Balance sheet
Mirati Therapeutics Inc 's Income	$ -162 million	Quarterly MRTX's Income Statement
MRTX's Income by Division		See MRTX's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018
Y / Y Total Assets Change	-26.43 %	10.4 %	232.97 %	89.18 %	45.28 %
Total Assets in million	1,169	1,589	1,439	432	228
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-741	-582	-358	-213	-98
Annual Return On Assets	-63.38 %	-36.62 %	-24.87 %	-49.34 %	-43.08 %

MRTX's 5 Years Annual ROA >> Back to MRTX Management Effectiveness >> Compare MRTX ROA to its Competitors

More Return On Assets Ratios
MRTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MRTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MRTX's Competitors
Subscribers only: Roa for Mirati Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for MRTX's Customers

You may also want to know
MRTX's Roi	MRTX's Inventory Turnover Ratio	MRTX's Growth Rates	MRTX's Dividend Comparisons
	MRTX's Profitability Ratios	MRTX's Asset Turnover Ratio	MRTX's Dividend Growth
MRTX's Roe	MRTX's Valuation Ratios	MRTX's Financial Strength Ratios	MRTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.